Interim results from a Phase I/II trial of anti-CD47 IgG2 mAb AO-176 demonstrated a good tolerability profile and possible anti-tumour activity, with 1 PR and 7 SD from 27 patients with advanced solid tumours (Table 1) [26]. Here, CD47 is linked to neoplasm.